Royalty Pharma PLC
NASDAQ:RPRX
Income Statement
Earnings Waterfall
Royalty Pharma PLC
Revenue
|
2.4B
USD
|
Operating Expenses
|
-862.4m
USD
|
Operating Income
|
1.5B
USD
|
Other Expenses
|
-357.3m
USD
|
Net Income
|
1.1B
USD
|
Income Statement
Royalty Pharma PLC
Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||
Revenue |
1 814
N/A
|
1 880
+4%
|
1 934
+3%
|
2 008
+4%
|
2 122
+6%
|
2 194
+3%
|
2 239
+2%
|
2 286
+2%
|
2 290
+0%
|
2 279
0%
|
2 260
-1%
|
2 247
-1%
|
2 237
0%
|
2 359
+5%
|
2 361
+0%
|
2 324
-2%
|
2 355
+1%
|
|
Operating Income | ||||||||||||||||||
Operating Expenses |
809
|
674
|
702
|
606
|
(462)
|
(762)
|
(470)
|
(700)
|
(859)
|
(857)
|
(1 206)
|
(1 304)
|
(1 314)
|
(1 793)
|
(1 924)
|
(1 928)
|
(862)
|
|
Selling, General & Administrative |
(103)
|
(117)
|
(130)
|
(155)
|
(182)
|
(187)
|
(189)
|
(187)
|
(183)
|
(191)
|
(198)
|
(200)
|
(227)
|
(261)
|
(257)
|
(264)
|
(250)
|
|
Research & Development |
(83)
|
(68)
|
(52)
|
(34)
|
(26)
|
(21)
|
(19)
|
(104)
|
(200)
|
(298)
|
(295)
|
(230)
|
(177)
|
(77)
|
(77)
|
(102)
|
(52)
|
|
Depreciation & Amortization |
(24)
|
(23)
|
(23)
|
(23)
|
(23)
|
(23)
|
(23)
|
(23)
|
(23)
|
(23)
|
(17)
|
(12)
|
(6)
|
0
|
0
|
0
|
0
|
|
Other Operating Expenses |
1 019
|
881
|
906
|
818
|
(231)
|
(531)
|
(240)
|
(386)
|
(453)
|
(345)
|
(695)
|
(862)
|
(904)
|
(1 454)
|
(1 590)
|
(1 562)
|
(561)
|
|
Operating Income |
2 623
N/A
|
2 554
-3%
|
2 635
+3%
|
2 613
-1%
|
1 661
-36%
|
1 433
-14%
|
1 768
+23%
|
1 586
-10%
|
1 431
-10%
|
1 421
-1%
|
1 054
-26%
|
943
-11%
|
923
-2%
|
566
-39%
|
437
-23%
|
397
-9%
|
1 492
+276%
|
|
Pre-Tax Income | ||||||||||||||||||
Interest Income Expense |
(162)
|
(374)
|
(32)
|
198
|
139
|
315
|
185
|
(33)
|
(184)
|
(203)
|
(151)
|
(31)
|
(62)
|
61
|
47
|
(20)
|
230
|
|
Non-Reccuring Items |
0
|
0
|
0
|
(25)
|
(96)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(616)
|
0
|
0
|
0
|
0
|
|
Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Other Income |
0
|
(6)
|
(5)
|
(4)
|
(2)
|
4
|
3
|
1
|
(6)
|
(8)
|
(8)
|
(18)
|
(15)
|
(16)
|
(14)
|
(5)
|
(22)
|
|
Pre-Tax Income |
2 461
N/A
|
2 174
-12%
|
2 598
+19%
|
2 782
+7%
|
1 702
-39%
|
1 752
+3%
|
1 957
+12%
|
1 554
-21%
|
1 241
-20%
|
1 210
-2%
|
895
-26%
|
894
0%
|
230
-74%
|
611
+166%
|
471
-23%
|
373
-21%
|
1 700
+356%
|
|
Net Income | ||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Income from Continuing Operations |
2 461
|
2 174
|
2 598
|
2 782
|
1 702
|
1 752
|
1 957
|
1 554
|
1 241
|
1 210
|
895
|
894
|
230
|
611
|
471
|
373
|
1 700
|
|
Income to Minority Interest |
(113)
|
(122)
|
(255)
|
(558)
|
(727)
|
(779)
|
(985)
|
(771)
|
(622)
|
(608)
|
(429)
|
(387)
|
(187)
|
(279)
|
(216)
|
(188)
|
(565)
|
|
Net Income (Common) |
2 349
N/A
|
1 981
-16%
|
1 863
-6%
|
1 745
-6%
|
495
-72%
|
564
+14%
|
972
+72%
|
783
-19%
|
620
-21%
|
602
-3%
|
466
-23%
|
507
+9%
|
43
-92%
|
332
+675%
|
255
-23%
|
184
-28%
|
1 135
+515%
|
|
EPS (Diluted) |
3.94
N/A
|
3.33
-15%
|
5.26
+58%
|
4.71
-10%
|
1.32
-72%
|
0.92
-30%
|
1.6
+74%
|
1.28
-20%
|
1.49
+16%
|
0.99
-34%
|
0.76
-23%
|
0.83
+9%
|
0.1
-88%
|
0.54
+440%
|
0.42
-22%
|
0.3
-29%
|
1.88
+527%
|